Diabetes prevention in Australia: 10 years results and experience by Dunbar, James A.
 DRO  
Deakin Research Online, 
Deakin University’s Research Repository  Deakin University CRICOS Provider Code: 00113B 
Diabetes prevention in Australia: 10 years results and experience 
Citation:  
Dunbar, James A. 2017, Diabetes prevention in Australia: 10 years results and experience, Diabetes & 
metabolism journal, vol. 41, no. 3, pp. 160-167. 
DOI: 10.4093/dmj.2017.41.3.160 
 
 
 
 
 
©2017, Korean Diabetes Association 
Reproduced by Deakin University under the terms of the Creative Commons Attribution Non-
Commercial Licence 
 
 
 
 
 
 
Downloaded from DRO: 
http://hdl.handle.net/10536/DRO/DU:30100568 
 
D I A B E T E S  &  M E T A B O L I S M  J O U R N A L
This is an Open Access article distributed under the terms of the Creative Commons 
Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) 
which permits unrestricted non-commercial use, distribution, and reproduction in any 
medium, provided the original work is properly cited.
Copyright © 2017 Korean Diabetes Association http://e-dmj.org
Diabetes Prevention in Australia: 10 Years Results and 
Experience
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Clinical trials have demonstrated the efficacy of lifestyle modification for the prevention of type 2 diabetes mellitus but it was 
achieved at higher cost than can be sustained in routine health services. The first clinical trial to report was the Finnish Diabetes 
Prevention Study. This paper describes how Australia worked with Finnish colleagues to adapt the findings of that study to 
achieve a statewide diabetes prevention program. Small evaluative, effectiveness trials have been conducted in a number of coun-
tries to see if the results of the clinical trials can be replicated in routine health services. The Australian evaluative trial, Greater 
Green Triangle Diabetes Prevention Program is described in detail to demonstrate the ingredients for success in moving a pro-
gram from one country to another. Few countries have managed to scale up from evaluative trials to statewide or national pro-
grams. The Australian experience is described in detail including lessons learned about what reduced the effectiveness, particu-
larly the need for policy makers in government, people from the implementing organisation and researchers to work together 
from the start of the evaluative trial and throughout the first 5 years of a national program.
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INTRODUCTION
It is widely recognised that the incidence of type 2 diabetes 
mellitus (T2DM) is high and increasing both in Australia [1] 
and throughout the world [2]. T2DM is a chronic and costly 
disease associated with premature mortality and high rates of 
health service utilisation linked with cardiovascular disease 
(CVD), retinopathy, renal failure and neuropathy [3].
The risk factors associated with T2DM onset are largely pre-
ventable. Lifestyle modification, particularly weight loss and 
physical activity, can significantly reduce the risk of T2DM [4-
7]. Diabetes prevention trials using lifestyle modification have 
been proven to be effective in reducing the risk of developing 
T2DM, and have been shown to be more effective than phar-
macological interventions [7-9]. The Finnish Diabetes Preven-
tion Study (DPS) [4,5] investigated the role of lifestyle inter-
ventions in the progression of T2DM among individuals with 
impaired glucose tolerance. Results demonstrated that the in-
cidence of T2DM decreased by 58% in the intervention group 
compared with the control group, a finding which was directly 
associated with lifestyle modification (Fig. 1). Two other stud-
ies have demonstrated similar results [6,7]. Randomised con-
trolled trials with one-to-one counselling and trials using 
drugs are expensive [8-10]. The lifestyle interventions have all 
lasted several years [5,7,11] and for example in the Finnish 
DPS, the median number of counselling sessions during a 
3-year intervention was 20 [4]. The aim of this paper is to de-
scribe the experience of moving from clinical trials, through 
evaluative trials to scaling up diabetes prevention at the state or 
national level.
Review
Obesity and Metabolic Syndrome
https://doi.org/10.4093/dmj.2017.41.3.160
pISSN 2233-6079 · eISSN 2233-6087
Diabetes Metab J 2017;41:160-167
Diabetes prevention in Australia
161Diabetes Metab J 2017;41:160-167http://e-dmj.org
EVIDENCE FROM EVALUATIVE TRIALS
Evaluative trials are effectiveness trials in the real world with a 
small number of participants usually fewer than 500. If clinical 
trials show what can be done, evaluative trials show how to do 
it. To determine whether the results obtained in clinical trials 
could be replicated in the ‘real world’ of primary health care set-
tings with limited resources and existing personnel, the Good 
Ageing in Lahti region (GOAL) intervention study, a lifestyle 
modification trial using a structured group program was de-
signed in Finland [12]. Whilst the implementation of lifestyle 
modification interventions in routine healthcare posed a great-
er challenge, the results of this program demonstrated that 
group lifestyle counselling can be effective and feasible in real-
world settings for individuals with an elevated risk of T2DM. 
Greater Green Triangle Diabetes Prevention Program
Greater Green Triangle Diabetes Prevention Program (GGT 
DPP) was based closely on the design of GOAL and estab-
lished in close collaboration with Finnish colleagues with 237 
participants in a pre-test, post -test design. Patients were re-
cruited at local general practices and screened using the Finn-
ish diabetes risk score (FINDRISC).
The intervention consisted of six structured, 90-minute 
group sessions over 8 months using the Health Action Process 
Approach (HAPA). The psychological changes resulting from 
the HAPA approach predicted behaviour changes resulting in 
12-month biophysical changes and support the theoretical ba-
sis of the intervention (Fig. 2) [12-16]. 
The first five sessions occurred within 3 months with 2-week 
intervals between sessions. The last session took place at 8 
months (Fig. 3). The sessions were facilitated by specially trained 
nurses, dieticians, and physiotherapists. A goal setting ap-
proach was used to motivate individuals to progress from in-
tention to actual behaviour change. Regular self-monitoring 
and feedback was used to empower patients to take responsi-
bility for their own decisions and to make informed choices. 
Session content for diet and physical activity was based on the 
dietary guidelines for Australian adults and the national physi-
cal activity guidelines. Social support was enhanced by the 
group setting and by encouraging participants to seek support 
from their own social networks. Intervention targets followed 
the lifestyle targets in the Finnish DPS aiming to reduce weight, 
total and saturated fat intake and increase fibre intake and 
physical activity. They are (1) no more than 30% of energy con-
sumed from fat; (2) no more than 10% of energy from saturat-
ed fat; (3) at least 15 g fibre/1,000 kcal; (4) at least 30 minutes/
day of moderate intensity physical exercise; and (5) at least 5% 
Fig. 1. Persistence of the benefit from lifestyle modification over 13 years; 9 years after the randomised control trial ended: com-
parison of (A) fasting plasma glucose and (B) 2-hour plasma glucose levels among intervention and controls. Adapted from Lind-
strom et al. [5], with permission from Springer.
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weight reduction. There is a linear relationship between the 
number of goals achieved and diabetes prevention (Fig. 4). 
At 12 months participants’ mean weight was reduced by 2.52 
kg and waist circumference by 4.17 cm. Mean fasting glucose 
reduced by 0.14 mmol/L, plasma glucose 2 hours after oral 
glucose challenge by 0.5 mmol/L, total cholesterol by 0.29 
mmol/L, low density lipoprotein by 0.25 mmol/L, triglycerides 
were 0.15 mmol/L, and diastolic blood pressure by 2.1 mm Hg. 
The study provided evidence that a T2DM prevention pro-
gram using lifestyle intervention was feasible in primary health 
care settings, with reductions in risk factors approaching those 
observed in clinical trials. 
Encouraging results from small evaluative efficacy trials 
conducted in Finland [12], USA [17-19], UK [20], GGT DPP 
[15], and Sydney DPP [21] in Australia, have contributed to 
evidence in this field. The Diabetes in Europe-Prevention us-
ing Lifestyle, Physical Activity and Nutritional Intervention 
Fig. 2. The Health Action Process Approach model for behavioural change showing the behavioural theories applicable from ses-
sions 1 to 6. Adapted from Schwarzer [16]. 
Fig. 3. Timeline in months for the Greater Green Triangle Dia-
betes Prevention Program showing timing of clinical testing 
and group counselling sessions. 
Fig. 4. Relationship between the number of goals of the Finn-
ish Diabetes Prevention Study achieved and hazard ratio for 
progression to type 2 diabetes mellitus after 13 years, adjusted 
for baseline age, body mass index, 2-hour glucose, and sex. Fig. 
4 was drawn by Prof Lindstrom at the National Institute of 
Health and Welfare, Helsinki. She has advised that permission 
has been given by the Institute. 
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(DE-PLAN study) involved many European countries [22]. A 
systematic review has shown that many of the evaluative trials 
have demonstrated positive results but they were on a small 
scale [23]. Once high-risk individuals attended the interven-
tions, and especially if the intervention dose was large enough 
and evidence-based protocols adhered to, participants benefit-
ed from the lifestyle modification.
FORMATION OF DIABETES PREVENTION 
POLICY IN AUSTRALIA
The argument that convinced the Australian Government to 
have a diabetes prevention program arose from the impact on 
the working population of the growing preventable chronic 
disease prevalence. At the time, only half of the cases of diabe-
tes were diagnosed and a quarter of the Australian population 
was at high risk of diabetes. During 2004 to 2006, work was un-
dertaken by the Council of Australian Governments (COAG) 
on a new economic reform agenda to ensure Australia’s pros-
perity in a global market. COAG subsequently announced a 
first tranche of human capital reforms include a specific focus 
on diabetes. 
Further in 2006, as part of the work undertaken for COAG, 
the GGT DPP was identified as the only evidence-based diabe-
tes prevention intervention in Australia. Combined evidence 
obtained from diabetes prevalence, economic analysis, scien-
tific evidence of diabetes prevention effectiveness from ran-
domised controlled trials, and the GGT DPP results strengthen 
the case for a national policy on diabetes prevention.
SCALING UP FROM EVALUATIVE TRIALS: 
IMPLEMENTATION OF LARGE-SCALE 
DIABETES PREVENTION PROGRAMS
Understanding how to implement interventions on a large-
scale is the next step in the process of translating diabetes pre-
vention research into population level strategies which cover-
ing a state or nation. Knowledge about the effectiveness of in-
terventions, their acceptability, uptake, reach, cost and how 
they work in different population subgroups and via which 
mechanisms, is particularly important for public health re-
search, practice, and policy. Evaluations of this kind can deter-
mine program intensity, fidelity, and sustainability in the long 
term. 
Finland was the first country to undertake a large-scale dia-
betes prevention intervention (DEHKO 2000–2010). A com-
munity-based high risk program in primary and occupational 
care to prevent T2DM, called the National Diabetes Prevention 
Programme in Finland: FIN-D2D was developed [24]. It 
achieved an average of 1kg weight loss which represents a 16% 
reduction in the risk of T2DM.
Implementation of large-scale diabetes prevention 
programs in Australia 
COAG in 2007 agreed to establish a national approach to pre-
vention of T2DM in high risk individuals and the Australian 
Government funded $217 million from 2007 to 2011 with a 
number of elements including:
(1)  Developing the Australian T2DM Diabetes Risk Assess-
ment tool (AusDRISK)
(2)  Establishing national standards for evidence based, in-
tensive lifestyle behaviour change (lifestyle modification 
programs)
(3)  Introducing a new medicare item for T2DM risk assess-
ment in 40 to 49 years age
(4)  Funding intensive lifestyle behaviour change interven-
tions (lifestyle modification programs) for the 40 to 49 
age group through a contract with the peak body for 
General Practice (Family Medicine). 
Some of this was successful but there were major implemen-
tation issues with the 40 to 49 age group program and uptake 
was well below expectations. Funding was discontinued in 
2011 (see below).
‘Life!’ Taking Action on Diabetes program
From 2007 to 2011, ‘Life!’ was a Victorian statewide, group 
based lifestyle intervention targeting 25,000 Victorians over 
the age of 50 at high risk of T2DM [25]. ‘Life’ consists of pre-
defined protocol of components including a strictly defined in-
tervention based on the GGT DPP, including the HAPA model 
for behavioural change, standardised facilitator training and 
manual, and a participant manual to record the lipid, blood 
pressure, and blood glucose levels plus their individualised 
goals and outcomes. Payment to facilitators was linked to data 
returned to use for continuous quality improvement and eval-
uation. The HAPA behaviour change theories were used to en-
courage participants to identify the main determinants of in-
tention building and make lifestyle changes associated with 
healthy diet and active lifestyle; thus, reducing the risk of that 
T2DM and CVD.
Dunbar JA
164 Diabetes Metab J 2017;41:160-167 http://e-dmj.org
The five goals of the Finnish DPS were retained
Participants were individuals aged 50 years or over with an 
AusDRisk score of >12- or, aged 18-year-old indigenous Aus-
tralians with an AusDRisk score of >12, aged 18 years or older 
with previously diagnosed high-risk conditions such as gesta-
tional diabetes or atherosclerosis related CVD.
‘Life!’ provided an opportunity to evaluate the effectiveness 
of such a large-scale prevention program, and importantly the 
cost-effectiveness through the Melbourne Diabetes Prevention 
Study (MDPS) which was an RCT that evaluated the efficacy 
and effectiveness of ‘Life!’ by monitoring participants’ clinical 
and behavioural outcomes before and after the intervention 
[26]. Participants were randomly allocated to receive the inter-
vention or receive usual care during the same time period. An 
economic assessment of ‘Life!’ was also included in the MDPS 
to determine its ‘value-for-money.’ The MDPS has also provid-
ed the opportunity to evaluate implementation of an evidence-
based diabetes prevention program in the real world. 
PPS analysis demonstrated that intervention participants 
significantly improved their weight (–1.13 kg), waist circum-
ference (–1.35 cm), systolic blood pressure (–5.2 mm Hg), and 
diastolic blood pressure (–3.2 mm Hg) compared with con-
trols. Based on observed weight change, estimated risk of de-
veloping diabetes reduced by 9.6% in the intervention group 
and increased by 3.3% in the control participants. Absolute 
5-year CVD risk reduced significantly for the intervention par-
ticipants by 0.97% points. In control participants, the risk in-
creased by 0.11% points. The net effect for the change in CVD 
was –1.08% points of absolute risk. The MDPS effectively re-
duced the risk of diabetes and CVD but the intervention effect 
on weight and waist reduction was modest due to the chal-
lenges in recruiting high-risk individuals and the abbreviated 
intervention (see below).
Four years ago, the Centers for Disease Control and Preven-
tion (CDC) launched the US National Diabetes Prevention 
Program largely delivered through YMCA. No outcomes have 
been published yet [27]. 
This year National Health Service (NHS) England launched 
the NHS Diabetes Prevention Programme in a pilot phase for 
20,000 individuals. It is unclear if the intervention is based on 
previous English research or whether the intervention has 
been modified by Public Health England. It will be sometime 
before the outcomes of the programme are known [28].
In summary, only a small number of countries where evalu-
ative trials have been completed have successfully scaled up 
programs nationally.
LESSONS LEARNED FROM SCALING UP
‘Program drift’ is the deviation from protocol resulting in re-
duced effect. ‘Voltage drop’ denotes the reduced benefits of dia-
betes prevention programs when they move from efficacy tri-
als to the real world [29]. In this section, lessons learned the 
hard way in Australia are recorded for the benefit of those de-
signing national diabetes prevention programs.
Glasgow argues that there should be no ‘program drift’ or 
‘voltage drop’ because programs should be built with quality 
improvement approaches aiming to achieve the performance 
levels of randomised controlled trials [29]. Australian experi-
ence suggests that effects and benefits could be improved. 
What is missing is continual measurement of performance in 
attaining the five goals of the Finnish DPS, and reductions in 
cholesterol and blood pressure. These are the known predic-
tors of clinical outcomes. The techniques of clinical audit such 
as ‘Plan-Do-Study-Act’ cycles should be applied to all aspects 
of program delivery. 
The commonest problem is that government plans scaled up 
programs without taking advice early enough from the re-
searchers who have conducted the evaluative trial. The level of 
funding and numbers of participants for the ‘Life!’ program 
were set without reference to the GGT DPP research team. 
This resulted in one session fewer, and less use of self-monitor-
ing and feedback. 
There were other problems. The payments to Life providers 
did not pay for the last session at 8 months and many of these 
sessions were not held. There was no check on fidelity of deliv-
ery or validation of the data returned by facilitators which was 
of poor quality. In short, there was no quality improvement 
program. 
Medicare rules did not permit retesting for cholesterol and 
repeat blood pressure measurements were not taken losing key 
opportunities for monitoring and feedback to reduce CVD 
risk. 
Too often politics impairs performance. The target of 25,000 
participants within 4 years was highly unrealistic and led to a 
senseless decision to reduce the AusDRISK entry score from 
>15 to >12. It resulted in a large recruitment of people at low 
risk both for diabetes and CVD. Indeed, MDPS demonstrated 
that AusDRISK >15 recruited too many people at low risk 
[26]. Diabetes prevention programs should only accept partici-
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pants with AusDRISK scores >15 and impaired fasting glu-
cose, impaired glucose tolerance, or glycosylated hemoglobin 
5.7 to 6.4. These criteria also apply to women who have had 
gestational diabetes [30].
The abbreviated program used in ‘Life!’ has inadequate time 
for repeated self-monitoring and feedback which is so impor-
tant for behavioural change. This shows as low attainment of 
the five goals of the Finnish DPS [26].
When participants leave diabetes prevention programs, the 
proportion at high cardiovascular risk will have dropped from 
a third to a quarter. It is important that those continuing at 
high CVD risk are referred back to their general practitioner 
(family physician) for medication [31].
In most countries we have seen poor handover from the re-
searchers who have undertaken the evaluative trials to the ser-
vice providers (implementers) who must scale up across large 
populations. Usually government processes interrupt the 
handover. These processes in Australia were so bad that it led 
to the end of the program for participants aged 40 to 49 years. 
It happened because the government put the program out to 
tender without drawing on the experience of the evaluative tri-
al, and the contractor had little relevant experience. Conse-
quently both published and tacit knowledge for implementa-
tion were lost. Worse still, the government took the view that 
the contractor had signed the contract and that all responsibil-
ity rested with it. This is exactly contrary to what has been 
known about effective implementation for over 30 years [32]. 
Successful implementation requires policymakers, imple-
menters, and researchers to work together to solve the problems 
which occur when even the best programs are tested the real 
world [32]. It is not good enough for government to say that it is 
someone else’s problem because they have signed a contract. All 
too often this approach results in implementation failure and 
wasted taxpayers’ money. This also happens if the implementers 
do not use to the researchers’ advice about how the program 
needs modified in the light of the research findings. 
The implementer also needs to make sure that there is not 
skills fade in facilitators or mission creep due to external pres-
sures. For instance ‘Life!’ is now promoted as a diabetes and 
CVD prevention program. It has not been modified in the light 
of research findings [33]. 
There remains a paucity of data to assess the long-term clini-
cal and economic impact of diabetes prevention programs [34-
37]. While there have been some modelling studies that have 
determined that lifestyle intervention is cost-effective for those 
with impaired glucose regulation uncertainties exist about 
model parameters, real costs and benefits of screening, and 
practical considerations about the affordability, acceptability, 
and feasibility of interventions.
CONCLUSIONS
In summary, to develop a national diabetes prevention pro-
gram in South Korea will require active co-operation between 
policymakers, implementers, and researchers over several 
years. This team work should start when plans for the evalua-
tive trial are underway and continue through every stage of 
scaling up to the national program and its evaluation over the 
first 5 years.
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